The UK Department of Health and Social Care has released an updated Group Direction (VGD) template to standardise the administration of seasonal influenza vaccines across England’s immunisation programmes for 2024–25. The template provides clinical guidance for both inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) delivery, enabling pharmacists, nurses, and other qualified healthcare professionals to administer vaccines under a group protocol without individual prescriptions.
Key takeaways
- Updated VGD template aligns influenza vaccine delivery with the UK’s national seasonal flu programme standards
- Framework authorises multiple healthcare professional groups—including pharmacists and specialist nurses—to administer both IIV and LAIV formulations
- Template includes contraindications, patient eligibility criteria, and post-vaccination safety monitoring protocols
- Standardised approach aims to reduce administrative burden and increase vaccine accessibility across primary and community care settings
Influenza Vaccine Delivery Pathway Under UK Group Direction
Authorised healthcare professionals and vaccine types in the 2024–25 national programme
Source: UK Department of Health and Social Care, 2024 | Georgian Medical Journal News
Streamlined Vaccination Protocol Reduces Prescribing Barriers
Group Direction protocols are legal instruments that permit specified healthcare professionals to supply and administer vaccines under a single authorisation, rather than requiring individual patient prescriptions. According to the UK Department of Health and Social Care’s updated template, this approach removes administrative delays and expands access to seasonal influenza immunisation in community pharmacies, general practices, and occupational health settings.
The framework specifies which patient populations qualify for each vaccine type—including pregnant women (IIV only), children aged 2–17 years (LAIV preferred where appropriate), and adults aged 50 years and over or those with chronic conditions. Healthcare professionals using the VGD must verify patient eligibility, screen for contraindications, and document vaccine administration in the national immunisation system.
Safety Monitoring and Clinical Contraindications Built Into Protocol
The template incorporates detailed contraindication criteria aligned with NICE immunisation guidance and the UK’s Green Book standards. Absolute contraindications to LAIV include severe immunosuppression, current systemic infection, and anaphylaxis to egg protein or vaccine components. For inactivated vaccines, the main exclusion is anaphylaxis to specific vaccine ingredients.
Healthcare professionals administering influenza vaccines under the VGD are required to observe patients for at least 15 minutes post-vaccination and maintain access to emergency resuscitation equipment. The protocol mandates reporting of serious adverse events to the MHRA Yellow Card scheme, ensuring pharmacovigilance continuity across all provider settings.
Standardisation Supports Equitable Access and Workforce Flexibility
By providing a single, nationally approved template, the VGD approach removes variability in vaccine delivery protocols across England’s four nations and different healthcare settings. This standardisation enables pharmacists and nurses to work within a consistent legal and clinical framework, reducing training fragmentation and enabling rapid workforce mobilisation during peak immunisation periods.
The Department of Health and Social Care template also simplifies integration with digital immunisation records and GP practice management systems, supporting real-time eligibility checking and preventing duplicate vaccinations. This interoperability is particularly valuable for mobile populations and individuals accessing care across multiple providers.
What this means
The updated VGD template authorises multiple healthcare professional groups to administer both inactivated and live attenuated influenza vaccines under a single legal protocol, removing individual prescribing requirements and standardising contraindication screening across primary and community care settings.
— UK Department of Health and Social Care, Influenza Vaccine Group Direction Template, 2024
Frequently asked questions
Which healthcare professionals can administer flu vaccines under the VGD?
According to the UK Department of Health and Social Care template, authorised professionals include pharmacists (community and hospital), practice nurses, health visitors, and school nurses. Each professional group has defined scopes aligned with their registration and training.
Can the same VGD be used for both inactivated and live attenuated influenza vaccines?
Yes. The updated template covers both IIV and LAIV within a single Group Direction document. However, eligibility criteria differ—LAIV is contraindicated in pregnant women and severely immunocompromised patients, while IIV is the standard for these populations.
How does the VGD integrate with digital immunisation records?
The template supports integration with national immunisation management systems and GP practice software, enabling real-time eligibility verification and duplicate vaccination prevention. Administered vaccines must be recorded in the national system within specified timeframes.
As the 2024–25 flu season approaches, the updated VGD template provides English healthcare systems with a robust, legally sound framework for efficient, equitable vaccine delivery. The shift toward community-based immunisation—underpinned by standardised protocols and clear safety guardrails—reflects international best practice in optimising seasonal influenza coverage while reducing administrative burden on primary care. Future monitoring of vaccine uptake rates and adverse event reporting under this streamlined approach will help evaluate its effectiveness in meeting national immunisation targets.
Source: UK Department of Health and Social Care — Influenza vaccine group direction (VGD) template
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
